Accessibility Menu
Vertex Pharmaceuticals logo

Vertex Pharmaceuticals(NASDAQ) VRTX

Current Price$470.83
Market Cap$119.94BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (1991)+10,611%
5 Year+136%
1 Year+1%
1 Month+1%
Vertex Pharmaceuticals last closing stock price
MetricPriceDate
Last closeUSD 472.572026-07-22
Vertex Pharmaceuticals stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-0.95%USD 477.082026-07-15
1 month+1.24%USD 466.792026-06-22
3 month+8.61%USD 435.102026-04-23
Year to date+4.24%USD 453.362025-12-31
1 year+0.52%USD 470.132025-07-22
3 year+30.38%USD 362.462023-07-21
5 year+135.7%USD 200.502021-07-23
Since inception+10,611.11%USD 4.501991-07-24

Vertex Pharmaceuticals Financials at a Glance

Market Cap

$119.94BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$12.26B

Net Income (TTM)

$4.34B

EPS (TTM)

$16.87

P/E Ratio

28.01

Dividend

$0.00

Beta (Volatility)

0.58 (Low)

Price

$470.83

Volume

4,640

Open

$466.29

Previous Close

$472.57

Daily Range

$466.29 - $472.74

52-Week Range

$362.50 - $533.67

Estimated Earnings Date

Aug 3, 2026

VRTX News

Vertex Pharmaceuticals logo

Vertex Pharmaceuticals Just Made a $10 Billion Acquisition Worth Watching

Prosper Junior BakinyJul 19, 2026
A biotech lab technician using multiple pipettes to load blood samples into test tubes.

5 Best Biotech Stocks for 2026 and How to Invest

Keith SpeightsJul 17, 2026
DNA with a healthcare professional in the background pointing to a lighted section of a DNA strand.

4 Best CRISPR Companies to Buy in 2026 and How to Invest

Keith SpeightsJul 14, 2026
people working in a lab

Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals

David Jagielski, CPAJul 14, 2026
A group of scientists looking at a report.

Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?

David Jagielski, CPAJul 13, 2026
Gene-editing-illustration

4 Best Gene-Editing Stocks for 2026 and How to Invest

Keith SpeightsJul 13, 2026
Vertex Pharmaceuticals logo

Is This Biotech Stock a Buy Near Its 52-Week High?

Prosper Junior BakinyJul 10, 2026
A scientist looking through a microscope.

5 Best Biotech ETFs for 2026 and How to Invest

Keith SpeightsJul 10, 2026
Page 1

VRTX: Motley Fool Moneyball Superscore

86

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Vertex Pharmaceuticals

Vertex creates medicines for people with serious genetic diseases. Its main drugs help those with cystic fibrosis breathe easier. The company also develops new treatments for pain and blood disorders.

Lab Bench to Bedside: Vertex’s Main Offerings

  • Cystic Fibrosis Therapies: Medicines like TRIKAFTA and KALYDECO treat lung problems in cystic fibrosis; TRIKAFTA/KAFTRIO accounted for approximately 93% of 2024 revenue.
  • Gene-Edited Cell Therapy: CASGEVY treats sickle cell disease and beta thalassemia, rare blood disorders; less than 1% of 2024 revenue.
  • Pain Management: JOURNAVX, a non-opioid pain drug, launched in the U.S. in 2025; no 2024 revenue.
  • Pipeline Programs: Early-stage drugs for diabetes, kidney, and autoimmune diseases; not yet generating revenue.

Growth Spurts and Global Moves

  • Acquired Alpine Immune Sciences in 2024 to expand into autoimmune diseases.
  • Launched ALYFTREK for cystic fibrosis in the U.S. in December 2024.
  • Launched JOURNAVX for pain in the U.S. in January 2025.
  • Secured global approvals for CASGEVY in the U.S. Europe, and other regions in 2024.
  • Formed partnerships with CRISPR Therapeutics, Moderna, and others to access new technologies.

Why Vertex Stands Out in the Crowd

Vertex sells its medicines in over 60 countries through specialty distributors and hospitals. The company focuses on diseases with clear genetic causes, using human biology to guide drug development. Its strategy includes rapid clinical testing and investing in advanced manufacturing for complex therapies.

Five Things You Need to Know

  • Net product revenue was $11.02 billion in 2024, up 12% from 2023.
  • TRIKAFTA/KAFTRIO made up 93% of 2024 product revenue.
  • U.S. sales were 61% of total revenue in 2024; international sales were 39%.
  • R&D spending was $3.63 billion in 2024, up 15% from 2023.
  • Operating loss was $232.9 million in 2024, due to a $4.6 billion acquisition expense.

Bottom Line

Vertex has evolved from a single-disease focus to a broader portfolio in rare and serious conditions. Its growth relies on innovation, global reach, and expanding beyond cystic fibrosis.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

6,400

CEO

Reshma Kewalramani, MD

Website

www.vrtx.com

Headquarters

Boston, MA 02210, US

VRTX Financials

Key Financial Metrics (TTM)

Gross Margin

86.28%

Operating Margin

38.97%

Net Income Margin

35.40%

Return on Equity

23.93%

Return on Capital

21.11%

Return on Assets

16.38%

Earnings Yield

3.57%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$119.94BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

253.81M

Volume

4.64K

Avg. Volume

1.51M

Financials (TTM)

Gross Profit

$10.57B

Operating Income

$4.78B

EBITDA

$5.39B

Operating Cash Flow

$4.24B

Capital Expenditure

-$530.30M

Free Cash Flow

$3.71B

Cash & ST Invst.

$7.25B

Total Debt

$1.99B

Vertex Pharmaceuticals Performance Analysis

Vertex Pharmaceuticals annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 8,748,200,00015.0%
20232023-12-31USD 9,839,000,00012.5%
20242024-12-31USD 10,984,400,00011.6%
20252025-12-31USD 12,074,600,0009.9%
Vertex Pharmaceuticals sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-307.0%
Q32025-09-303.8%
Q42025-12-314.9%
Q12026-03-31-7.4%
Vertex Pharmaceuticals annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD 12.8242.3%
20232023-12-31USD 13.898.4%
20242024-12-31USD -2.08N/A
20252025-12-31USD 15.32N/A
Vertex Pharmaceuticals sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3060.2%
Q32025-09-305.3%
Q42025-12-3110.7%
Q12026-03-31-13.5%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$2.99B

+7.8%

Gross Profit

$2.59B

+7.8%

Gross Margin

86.85%

N/A

Market Cap

$119.94BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$18.74M

N/A

Employees

6,400

N/A

Net Income

$1.03B

+59.6%

EBITDA

$1.31B

+67.4%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$7.25B

+16.9%

Total Debt

$1.99B

+20.5%

Accounts Receivable

$2.00B

+10.6%

Inventory

$1.77B

+29.9%

Long Term Debt

$1.99B

+20.5%

Short Term Debt

$0.00

N/A

Return on Assets

16.38%

N/A

Return on Invested Capital

21.13%

N/A

Free Cash Flow

$1.29B

+66.4%

Operating Cash Flow

$1.43B

+74.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SYKStryker Corporation
$317.91+2.80%
BMYBristol-Myers Squibb Company
$61.06+0.49%
MDTMedtronic plc
$82.28+0.48%
SNYSanofi
$43.11-1.56%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$8.20-0.25%
TQQQProShares Trust - ProShares UltraPro Qqq
$67.18-0.04%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$42.78+0.04%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$35.81+0.04%

Questions About VRTX

What is the current price of Vertex Pharmaceuticals?

Vertex Pharmaceuticals is trading at $470.91 per share.

What is the 52-week range for Vertex Pharmaceuticals?

Over the past 52 weeks, Vertex Pharmaceuticals has traded between $362.50 and $533.67.

How much debt does Vertex Pharmaceuticals have?

As of the most recent reporting period, Vertex Pharmaceuticals reported total debt of $1.99B.

How much cash does Vertex Pharmaceuticals have on hand?

Vertex Pharmaceuticals reported $5.50B in cash and cash equivalents in its most recent financial results.

What is Vertex Pharmaceuticals’s dividend yield?

Vertex Pharmaceuticals does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services